Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers

Clinical trial NCT02526316 · COMPLETED

Trial details

NCT number: NCT02526316
Sponsor: Oryx GmbH & Co. KG
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HPV-induced Cancers

Start date: 2015-06-01
Primary completion: 2017-05-01
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.